Seeking Alpha

Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai...

Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai (ESALY.PK), which will market the pill in the U.S. and apply for authorization in other countries in the Americas. SA author Red Acre Investments notes that what is not explicitly stated is that Eisai, not Arena, will run all of the pediatric and cardiovascular outcome trials that are required under Belviq's FDA approval letter (.pdf). (PR)
Comments (1)
  • topperg
    , contributor
    Comments (218) | Send Message
     
    ARNA $30---$50 buyout say no more we wait
    30 Jul 2012, 12:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs